Literature DB >> 20405117

Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension.

Robyn J Barst1, Gabriella Agnoletti, Alain Fraisse, James Baldassarre, David L Wessel.   

Abstract

The objective of this study was to determine whether a combination of inhaled nitric oxide (iNO) and O(2) is more effective than 100% O(2) or iNO alone for acute vasodilator testing in children. An open, prospective, randomized, controlled trial was conducted at 16 centers. Subjects were children 4 weeks to 18 years of age with pulmonary hypertension (PH) and increased pulmonary vascular resistance (PVR) undergoing right heart catheterization for acute vasodilator testing. All patients were tested with each of three agents (80 ppm iNO, 100% O(2), combination of 80 ppm iNO/100% O(2)) in three 10-min treatment periods, and hemodynamic measurements obtained. Primary outcome measures were percentages of acute responders with O(2) alone vs. iNO/O(2) and iNO alone vs. iNO/O(2). More patients on the combination were acute responders compared with O(2) or iNO alone (26% vs. 14%, P = 0.019, and 27% vs. 24%, P = 0.602, respectively). Changes in PVR index and mean pulmonary arterial pressure vs. baseline were greater with iNO/O(2) vs. either O(2) or iNO alone (P < 0.001). Survival at 1-year follow-up included (1) 90.9% of acute responders to the combination, compared with 77.8% of nonresponders to the combination, and (2) 85.7% of acute responders to O(2) alone, compared with 80.6% of nonresponders to O(2). Key conclusions are as follows. In children with PH and increased PVR, more acute responders were identified with the iNO/O(2) combination vs. O(2) alone. While there was no significant difference in acute responder rate with iNO alone vs. iNO/O(2), the combination improved pulmonary hemodynamics acutely better than iNO alone. One-year survival data show similar rates between the iNO/O(2) and the O(2) alone groups; however, the combination may be more effective than O(2) alone in discriminating survivors versus nonsurvivors at long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405117     DOI: 10.1007/s00246-010-9645-5

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  24 in total

1.  Incidents and complications during pediatric cardiac catheterization.

Authors:  Davinia Bennett; Ritchie Marcus; Monica Stokes
Journal:  Paediatr Anaesth       Date:  2005-12       Impact factor: 2.556

Review 2.  Diagnosis and assessment of pulmonary arterial hypertension.

Authors:  David B Badesch; Hunter C Champion; Miguel Angel Gomez Sanchez; Marius M Hoeper; James E Loyd; Alessandra Manes; Michael McGoon; Robert Naeije; Horst Olschewski; Ronald J Oudiz; Adam Torbicki
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

Authors:  Olivier Sitbon; Marc Humbert; Xavier Jaïs; Vincent Ioos; Abdul M Hamid; Steeve Provencher; Gilles Garcia; Florence Parent; Philippe Hervé; Gérald Simonneau
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

4.  Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology.

Authors:  R A Krasuski; J J Warner; A Wang; J K Harrison; V F Tapson; T M Bashore
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

5.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

6.  Vasodilator therapy for primary pulmonary hypertension in children.

Authors:  R J Barst; G Maislin; A P Fishman
Journal:  Circulation       Date:  1999-03-09       Impact factor: 29.690

7.  Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.

Authors:  R J Barst
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

8.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Authors:  O Sitbon; M Humbert; J L Jagot; O Taravella; M Fartoukh; F Parent; P Herve; G Simonneau
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

9.  Outcomes in children with idiopathic pulmonary arterial hypertension.

Authors:  Delphine Yung; Allison C Widlitz; Erika Berman Rosenzweig; Diane Kerstein; Greg Maislin; Robyn J Barst
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

10.  Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators.

Authors:  C Houde; D J Bohn; R M Freedom; M Rabinovitch
Journal:  Br Heart J       Date:  1993-11
View more
  18 in total

Review 1.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

Review 2.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

3.  Hyperoxia Reduces Oxygen Consumption in Children with Pulmonary Hypertension.

Authors:  Long Guo; Prashant Bobhate; Shine Kumar; Karunakar Vadlamudi; Tarek Kaddoura; Mohamed Elgendi; Paula Holinski; James Y Coe; Jennifer Rutledge; Ian Adatia
Journal:  Pediatr Cardiol       Date:  2017-03-18       Impact factor: 1.655

Review 4.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

Review 5.  Recent progress in understanding pediatric pulmonary hypertension.

Authors:  Steven H Abman; D Dunbar Ivy
Journal:  Curr Opin Pediatr       Date:  2011-06       Impact factor: 2.856

6.  Assessment of pulmonary arterial hypertension and vascular resistance by measurements of the pulmonary arterial flow velocity curve in the absence of a measurable tricuspid regurgitant velocity in childhood congenital heart disease.

Authors:  Ayhan Cevik; Serdar Kula; Rana Olgunturk; F Sedef Tunaoglu; A Deniz Oguz; Berna Saylan; Erman Cilsal; Cihat Sanli
Journal:  Pediatr Cardiol       Date:  2012-10-05       Impact factor: 1.655

Review 7.  Pulmonary Hypertension.

Authors:  Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

Review 8.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

9.  Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension.

Authors:  Shinichi Takatsuki; Donna K Parker; Aimee K Doran; Robert H Friesen; D Dunbar Ivy
Journal:  Pediatr Cardiol       Date:  2012-11-27       Impact factor: 1.655

10.  Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces.

Authors:  Maria Jesus Del Cerro; Shahin Moledina; Sheila G Haworth; Dunbar Ivy; Maha Al Dabbagh; Hanaa Banjar; Gabriel Diaz; Alexandria Heath-Freudenthal; Ahmed Nasser Galal; Tilman Humpl; Snehal Kulkarni; Antonio Lopes; Ana Olga Mocumbi; G D Puri; Beyra Rossouw; S Harikrishnan; Anita Saxena; Patience Udo; Lina Caicedo; Omar Tamimi; Ian Adatia
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.